Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Bone Marrow Aspirate Concentrate Use in Hip Osteoarthritis (BMAC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03410355
Recruitment Status : Not yet recruiting
First Posted : January 25, 2018
Last Update Posted : April 4, 2018
Sponsor:
Information provided by (Responsible Party):
Ivan Wong, Nova Scotia Health Authority

Brief Summary:
The purpose of this study is to evaluate the effect of combined Bone marrow aspirate concentrate (BMAC) and Platelet Rich Plasma (PRP) action after a single hip intraarticular injection to young symptomatic patients with primary radiologic stage of hip OA (Kellgren-Lawrence grade I or II) compared to a control local anesthetic with cortisone injection group of patients. The hypothesis is that the patients with hip OA will benefit more and for longer from OA symptoms in the BMAC and PRP group rather than in the group of local anaesthetic and cortisone. Furthermore, this study could be valuable in determining the safety and effectiveness of the BMAC and PRP combined injection for early low grade hip OA in young active patients who are neither good candidates for total hip replacement nor preservative hip surgery.

Condition or disease Intervention/treatment Phase
Osteoarthritis, Hip Procedure: BMAC/PRP Injection Procedure: Cortisone Injection Not Applicable

Detailed Description:

The protocol will be applied to a blinded randomized controlled study. Patients who fit the inclusion criteria and have consented to the trial, will be randomized to receive a single injection of BMAC with PRP or local anesthetic with cortisone.

Pre-Injection Procedures:

Patients will receive a clinical evaluation where they will complete the HHS, the WOMAC score, the VR-12 form, VAS score, and the two functional assessment tests to assess pain and function prior to the injection. The two functional assessments will be performed by the blinded researcher. Following the evaluation, the patients will receive an intra-articular hip injection.

Injection Procedures:

Control group: In the second group of patients, an intraarticular injection of 1cm3 with 80mg of methylprednisolone combined with 3cm3 of 0.25% bupivacaine will be performed in the same manner with the first group.

Experimental group: In the first group, patients will be placed on an office procedure under local anesthesia. The investigators will harvest 60 cm3 of bone marrow from posterior iliac crest and centrifuged obtaining approximately 3 cm3 of autologous bone marrow-mesenchymal stem cells concentrate. At the same time, 60cm3 of peripheral blood will be taken and centrifugated once, to obtain approximately 3 cm3 of PRP. After activation of platelet rich plasma cells they will be mixed in one syringe with the concentrated BMaC and both will be injected in the hip joint under ultrasound. In all cases four samples of 0.2cm3 will be collected, one with patient's whole blood, one with the PRPs final mixture, one with whole bone marrow aspirate, and one with the BMaCs final mixture, and will be sent to the NSHA Hematology Laboratory for cell quantification. The leukocyte counts and differential (neutrophils, monocytes, lymphocytes, eosinophils and basophils) as well as thrombocyte counts in all samples will be determined using Automated Hematology Analyzer (Sysmex). Percentages of mature and immature leukocytes in the bone marrow aspirate and BMaC samples will be determined by standard morphologic examination using slides prepared with the Wright's stain. CD34+ stem cell enumeration in the bone marrow aspirate sample and BMaC will be performed by flow cytometry (Canto II Analyser).The concentration factor of PRP will be calculated from the quotient of the thrombocyte count in whole blood and in PRP. Additionally, IGF-I, VEGF, TGF-b, bFGF, HGF and PDGF will be quantified in serum or plasma and in PRP using commercially available ELISA kits (QuantikineH, ELISA KITS, R&D Systems, USA).

Post-Injection Procedures:

Clinic visits will occur at 6, 12, 24, and 48 weeks post-injection to perform clinical evaluations with outcome measures of the patients. All collected data will be statistically analyzed to check the effect of BMAC and PRP intraarticular hip injections in young patients with early OA. The investigators will also document the activity level of all participants (type of sport or activity participated in and the intensity and volume of participation) and correlate it with the outcomes.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: randomized control trial
Masking: Single (Outcomes Assessor)
Masking Description: The outcomes assessor will be blinded to the intervention
Primary Purpose: Treatment
Official Title: The Use of Bone Marrow Aspirate Concentrate in the Context of Hip Osteoarthritis: A Randomized Controlled Trial
Estimated Study Start Date : June 2018
Estimated Primary Completion Date : June 2019
Estimated Study Completion Date : June 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Osteoarthritis

Arm Intervention/treatment
Experimental: BMAC/PRP Injection Group
This group will receive an injection of BMAC/PRP for treatment of OA
Procedure: BMAC/PRP Injection
Patients will be placed on an office procedure under local anesthesia. The investigators will harvest 60 cm3 of bone marrow from posterior iliac crest and centrifuged obtaining approximately 3 cm3 of autologous bone marrow-mesenchymal stem cells concentrate. At the same time, 60cm3 of peripheral blood will be taken and centrifugated once, to obtain approximately 3 cm3 of PRP. After activation of platelet rich plasma cells they will be mixed in one syringe with the concentrated BMaC and both will be injected in the hip joint under ultrasound.

Active Comparator: Cortisone Injection Group
This group will receive an injection of cortisone for treatment of OA
Procedure: Cortisone Injection
An intraarticular injection of 1cm3 with 80mg of methylprednisolone combined with 3cm3 of 0.25% bupivacaine will be injected in the hip joint under ultrasound.




Primary Outcome Measures :
  1. Functional Benefit and Pain Level Changes using iHOT33 Questionnaire [ Time Frame: 6 months ]
    Assessment of functional benefit and pain level changes, using the International Hip Outcome Tool (iHot33) score at the 6-month time point post-injection, as well as, the pre-injection iHot33 score. The iHOT33 is a 33 question tool used to assess a patients ability to return to an active lifestyle through a subjective measurement of symptoms as well as emotional and social health status. Patients use a visual analog type scale (VAS) for each of the 33 questions to determine if activities are extremely difficult (to the left) to not difficult at all (to the right). Score is calculated as a mean on all VAS scores measured in millimeters, with 100 being the best score and 0 being the worst.


Secondary Outcome Measures :
  1. Functional Benefit and Pain level Changes using the modified Harris Hip Score (HHS) [ Time Frame: 6 months ]
    The HHS is a widely used 10 item evaluation used to assess hip pain, function, hip deformity, and range of motion in patients who have total hip replacements, femoral neck fractures, and osteoarthritis. Each question is assigned a different numerical value. A score of 90-100 is excellent indicating minimal pain and excellent function, 80-89 is good, 70-79 fair, 60-69 poor, and below 60 a failed result.

  2. Functional Benefit and Pain level Changes using the The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) [ Time Frame: 6 months ]
    The WOMAC is a 24 item evaluation used in hip or knee OA to assess pain, stiffness, and physical function. This questionnaire measures five items for pain (score range 0-20), two for stiffness (score range 0-8), and 17 for functional limitation (score range 0-68). All questions ask participants to report their level of difficulty performing different tasks, 0 = None, 1 = Slight, 2 = Moderate, 3 = Very, 4 = Extremely. The score is calculated as a percentage of 96. With 100% being the worst and 0% being the best.

  3. Burden of Disease and Quality of Life Changes using the Veterans RAND 12 Item Health Survey (VR-12) [ Time Frame: 6 months ]
    This instrument is primarily used to measure health related quality of life, to estimate disease burden and to evaluate disease-specific impact on general and selected populations. The items on the questionnaire correspond to eight principal health domains including general health perceptions, physical functioning, role limitations due to physical and emotional problems, bodily pain, energy-fatigue, social functioning, and mental health.

  4. Pain Changes using the Visual Analogue Scale (VAS) [ Time Frame: 6 months ]
    The VAS is the most common pain scale for quantification of disease related pain.This consists of a horizontal line, 100 mm in length, anchored by word descriptors at each end, "no pain" and "very severe pain" respectively. The patient marks on the line the point that they feel represents their perception of their current state. The VAS score is determined by measuring in millimeters from the left-hand end of the line to the point that the patient marks. 100 mm=very severe pain, 0mm=no pain.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   16 Years to 60 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Age <60 years old
  • BMI of <40 kg/m2
  • Able to walk 50m unaided and not confined to a wheel chair
  • Unilateral hip pain and radiographically and arthroscopically verified OA of the hip within the last 6 months (Kellgren-Lawrence grade I or II)
  • HHS of less than 80
  • Ability to understand the informed consent and participation instructions Attempted to use over the counter therapy without relief
  • Able to participate for the entire protocol study period
  • Able to follow physicians directions

Exclusion Criteria:

  • Clinically significant OA in the contralateral hip
  • Clinically significant pain in any other joint
  • Have had intra-articular BMAC and or PRP injection within the preceding six months in the study hip
  • Have had intra-articular steroid injection within the preceding three months in the study hip
  • Have had previous surgical procedures on the affected hip within the preceding 6 months
  • Have had a serious injury to the study hip within the previous 3 months
  • Have had a serious psychological or medical condition that would interfere with their involvement
  • Have had treatment with pain medications other than Tylenol and the drug remains in their system at the baseline or first study visit
  • Have used of opioids other than weak opioids for OA pain more than 3 days/week within the last month
  • Have used of systemic glucocorticoids (excluding inhaled steroids) within the preceding 3 months
  • Treatment started with glucosamine/chondroitin sulfate or if the dosing has not been stable in the previous three months
  • Has had a history of septic arthritis, skin infection or disease in the region of the injection site
  • Currently using an anticoagulant excluding Aspirin 325 mg/day
  • Uncontrolled diabetes
  • Has any medical condition the principal investigator believes deems the patient unsuitable for the study
  • Has any pathology of lumbar spine, sacroiliac (SI) joints, neuropathic or extra-articular hip pain
  • Has a history of alcohol or drug abuse within the six months prior to enrolment in the study
  • Has had a diagnosis of rheumatoid arthritis
  • Has had a diagnosis of ankylosing spondylitis
  • Has had a diagnosis of psoriatic arthritis
  • Has had a diagnosis of reactive arthritis
  • Has had a diagnosis of gout
  • Has had a diagnosis of any connective tissue disease.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03410355


Contacts
Layout table for location contacts
Contact: Ivan Wong, MD (902)473-7626 research@drivanwong.com
Contact: Sarah MacLaughlin, MSc 4036515517 sarah@drivanwong.com

Sponsors and Collaborators
Nova Scotia Health Authority
Investigators
Layout table for investigator information
Principal Investigator: Ivan Wong, MD Nova Scotia Health Authority

Layout table for additonal information
Responsible Party: Ivan Wong, Orthopaedic Surgeon MD FRCS(C), Dip. Sports Medicine, Nova Scotia Health Authority
ClinicalTrials.gov Identifier: NCT03410355     History of Changes
Other Study ID Numbers: IW-001
First Posted: January 25, 2018    Key Record Dates
Last Update Posted: April 4, 2018
Last Verified: April 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes

Additional relevant MeSH terms:
Layout table for MeSH terms
Osteoarthritis
Osteoarthritis, Hip
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Cortisone
Anti-Inflammatory Agents